Piper Jaffray Reiterates Overweight Rating and $24 PT on vTv Therapeutics (VTVT) Following Positive GK Activator T2D Presentation
Tweet Send to a Friend
Piper Jaffray analyst Charles Duncan reiterates Overweight rating and $24 PT on vTv Therapeutics (NASDAQ: VTVT), suggesting GK Activator T2D ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
